Mark Z Hansen

US Patent:

20120260182, Oct 11, 2012

Filed:

Apr 8, 2011

Appl. No.:

13/083049

Inventors:

Mark H. HANSEN - West Hollywood CA, US
Jeremy Thorp - Brooklyn NY, US

Assignee:

The New York Times Company - New York NY

International Classification:

G06F 15/16
G06F 3/048

US Classification:

715736

Abstract:

A system for and method of generating and visualizing one or more sharing event cascade structures associated with one or more content sharing events that occur across a network may include generating a plurality of sharing event nodes in the one or more sharing event cascade structures based on data associated with at least one of a system log and a database, wherein each sharing event cascade structure graphically represents a history of one or more content items being shared among a plurality of users of the network, and presenting, on a display device, a content sharing visualization diagram that illustrates the one or more sharing event cascade structures and enables a user to analyze sharing patterns associated with the plurality of users of the network.

US Patent:

20130172389, Jul 4, 2013

Filed:

Dec 27, 2012

Appl. No.:

13/727860

Inventors:

Ellen Chao - Irvine CA, US
Herman Ng - Tustin CA, US
Hau Ton - Buena Park CA, US
Jia Chian Li - Irvine CA, US
Joseph S. Adorante - Irvine CA, US
Michael S. Garst - Newport Beach CA, US
Howard B. Rind - Laguna Niguel CA, US
Mark R. Hansen - San Diego CA, US
Alfred Arthur Avey - Eugene OR, US
Lloyd Jay Dolby - Eugene OR, US
Shervin Esfandiari - Eugene OR, US
Vivian R. MacKenzie - Eugene OR, US
Jeremiah Andrew Marsden - Eugene OR, US
David Charles Muchmore - Eugene OR, US

Assignee:

Allegan, Inc. - Irvine CA

International Classification:

C07D 235/12
C07D 235/08
C07D 403/12
C07D 403/06
C07D 401/12
C07D 235/14
C07D 235/06

US Classification:

514338, 5483101, 514394, 5483097, 5483044, 5483061, 5462734, 5483057

Abstract:

The present invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof; wherein R, R, R, R, R, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.